EU and US could reach trade deal this weekend - Reuters
SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a small-cap biotech company with a market capitalization of approximately $6 million, has unveiled a strategic plan to enhance financial performance and expedite the commercial expansion of CyPath® Lung, its noninvasive early-stage lung cancer detection test. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics, though investors should note the company’s challenging financial health score of 1.99 out of 5. The company anticipates these initiatives will yield approximately $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while reallocating resources to bolster CyPath® Lung sales in key national markets.
The cost-saving measures include a 38% reduction in PPLS’s workforce not directly related to CyPath® Lung, improvements in operational efficiency, and discontinuing certain low-margin pathology services. Despite an expected decrease in overall revenue, the company projects these actions will enhance PPLS’s profitability by concentrating on CyPath® Lung and other high-value services. InvestingPro data reveals the company’s urgent need for operational improvements, with an EBITDA of -$7.62 million in the last twelve months and a concerning cash burn rate. Get access to 10+ additional ProTips and comprehensive financial metrics with InvestingPro.
bioAffinity’s President and CEO, Maria Zannes, stated that the changes at PPLS are aligned with the company’s commercial strategy to accelerate market growth for CyPath® Lung. The firm aims to continue providing exceptional anatomical pathology services, a legacy of PPLS for over 25 years, while also focusing on its 2025 goals. These include starting enrollment for the FDA pivotal trial for CyPath® Lung and developing additional noninvasive diagnostics for diseases such as COPD and asthma.
Chief Financial Officer Michael Edwards highlighted the year-over-year sales growth of CyPath® Lung and the expectation of improved profitability from the strategic adjustments. Zannes added that the company is preparing to serve both civilian and military healthcare systems with CyPath® Lung, which has recently become available for purchase through the Federal Supply Schedule. A targeted government marketing program is set to launch next quarter to introduce the test to Veterans Administration and Department of Defense medical centers.
CyPath® Lung employs advanced flow cytometry and AI to analyze patient sputum samples for cancer-indicating cell populations. The test uses a fluorescent porphyrin that targets cancerous cells, demonstrating high sensitivity, specificity, and accuracy in clinical studies for detecting lung cancer in high-risk patients with small lung nodules. While analysts forecast sales growth for the current year, with revenue growth expectations of 278%, InvestingPro data indicates the company needs to address its profitability challenges, as reflected in its negative return on assets of -100.9%.
This news is based on a press release statement from bioAffinity Technologies.
In other recent news, bioAffinity Technologies, Inc. has received a notice from The Nasdaq Stock Market LLC for not meeting the minimum bid price requirement for its stock, which must close at or above $1.00 for ten consecutive business days by August 6, 2025. The company is exploring options to address this issue. Additionally, bioAffinity Technologies has secured a patent in Australia for its CyPath® Lung diagnostic test, enhancing its intellectual property portfolio. This development is expected to bolster the company’s market reach, with the patent remaining in force until 2042.
In corporate governance matters, the company has amended the employment agreement of its CEO, Maria Zannes, resulting in a salary increase to $300,000 annually, effective retroactively from November 1, 2024. Shareholders have also approved the issuance of up to 2,724,230 shares of common stock upon the exercise of warrants, a move that aligns with Nasdaq Listing Rules and strengthens the company’s capital base. Furthermore, bioAffinity Technologies recently conducted an investor webinar, providing updates on its research progress and commercial strategies, with the transcript now available in a Form 8-K filing. These developments reflect the company’s ongoing efforts to engage with investors and enhance its operational and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.